195 related articles for article (PubMed ID: 22785201)
21. Post-transcriptional regulation of programmed cell death 4 (PDCD4) mRNA by the RNA-binding proteins human antigen R (HuR) and T-cell intracellular antigen 1 (TIA1).
Wigington CP; Jung J; Rye EA; Belauret SL; Philpot AM; Feng Y; Santangelo PJ; Corbett AH
J Biol Chem; 2015 Feb; 290(6):3468-87. PubMed ID: 25519906
[TBL] [Abstract][Full Text] [Related]
22. Effects and expression of TRAIL and its apoptosis-promoting receptors in human pancreatic cancer.
Ozawa F; Friess H; Kleeff J; Xu ZW; Zimmermann A; Sheikh MS; Büchler MW
Cancer Lett; 2001 Feb; 163(1):71-81. PubMed ID: 11163110
[TBL] [Abstract][Full Text] [Related]
23. A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model.
Rajeshkumar NV; Rasheed ZA; García-García E; López-Ríos F; Fujiwara K; Matsui WH; Hidalgo M
Mol Cancer Ther; 2010 Sep; 9(9):2582-92. PubMed ID: 20660600
[TBL] [Abstract][Full Text] [Related]
24. Role of activating transcription factor 3 (ATF3) in endoplasmic reticulum (ER) stress-induced sensitization of p53-deficient human colon cancer cells to tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis through up-regulation of death receptor 5 (DR5) by zerumbone and celecoxib.
Edagawa M; Kawauchi J; Hirata M; Goshima H; Inoue M; Okamoto T; Murakami A; Maehara Y; Kitajima S
J Biol Chem; 2014 Aug; 289(31):21544-61. PubMed ID: 24939851
[TBL] [Abstract][Full Text] [Related]
25. A novel TRAIL mutant-TRAIL-Mu3 enhances the antitumor effects by the increased affinity and the up-expression of DR5 in pancreatic cancer.
Huang M; Zhu H; Yi C; Yan J; Wei L; Yang X; Chen S; Huang Y
Cancer Chemother Pharmacol; 2018 Nov; 82(5):829-838. PubMed ID: 30167846
[TBL] [Abstract][Full Text] [Related]
26. Caspase-mediated cleavage of RNA-binding protein HuR regulates c-Myc protein expression after hypoxic stress.
Talwar S; Jin J; Carroll B; Liu A; Gillespie MB; Palanisamy V
J Biol Chem; 2011 Sep; 286(37):32333-43. PubMed ID: 21795698
[TBL] [Abstract][Full Text] [Related]
27. Reduction of decoy receptor 3 enhances TRAIL-mediated apoptosis in pancreatic cancer.
Wang W; Zhang M; Sun W; Yang S; Su Y; Zhang H; Liu C; Li X; Lin L; Kim S; Okunieff P; Zhang Z; Zhang L
PLoS One; 2013; 8(10):e74272. PubMed ID: 24204567
[TBL] [Abstract][Full Text] [Related]
28. Upregulation of Death Receptor 5 and Production of Reactive Oxygen Species Mediate Sensitization of PC-3 Prostate Cancer Cells to TRAIL Induced Apoptosis by Vitisin A.
Shin D; Kwon HY; Sohn EJ; Nam MS; Kim JH; Lee JC; Ryu SY; Park B; Kim SH
Cell Physiol Biochem; 2015; 36(3):1151-62. PubMed ID: 26111475
[TBL] [Abstract][Full Text] [Related]
29. Insulin-like growth factor-I receptor is suppressed through transcriptional repression and mRNA destabilization by a novel energy restriction-mimetic agent.
Chu PC; Kulp SK; Chen CS
Carcinogenesis; 2013 Dec; 34(12):2694-705. PubMed ID: 23864387
[TBL] [Abstract][Full Text] [Related]
30. p53-dependent and -independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor alpha.
Sheikh MS; Burns TF; Huang Y; Wu GS; Amundson S; Brooks KS; Fornace AJ; el-Deiry WS
Cancer Res; 1998 Apr; 58(8):1593-8. PubMed ID: 9563466
[TBL] [Abstract][Full Text] [Related]
31. Regulation of DR-5 protein and mitochondrial transmembrane potential by gemcitabine, a possible mechanism of gemcitabine-enhanced TRAIL-induced apoptosis.
Seol JW; Chaudhari AA; Lee YJ; Kang HS; Kim IS; Kim NS; Park JH; Kim TH; Seol DW; Park SY
Oncol Rep; 2007 Sep; 18(3):523-9. PubMed ID: 17671697
[TBL] [Abstract][Full Text] [Related]
32. DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.
Yu R; Albarenque SM; Cool RH; Quax WJ; Mohr A; Zwacka RM
Cancer Biol Ther; 2014; 15(12):1658-66. PubMed ID: 25482930
[TBL] [Abstract][Full Text] [Related]
33. Dual Agonist Surrobody Simultaneously Activates Death Receptors DR4 and DR5 to Induce Cancer Cell Death.
Milutinovic S; Kashyap AK; Yanagi T; Wimer C; Zhou S; O'Neil R; Kurtzman AL; Faynboym A; Xu L; Hannum CH; Diaz PW; Matsuzawa S; Horowitz M; Horowitz L; Bhatt RR; Reed JC
Mol Cancer Ther; 2016 Jan; 15(1):114-24. PubMed ID: 26516157
[TBL] [Abstract][Full Text] [Related]
34. Death receptor 5 is activated by fucosylation in colon cancer cells.
Zhang B; van Roosmalen IAM; Reis CR; Setroikromo R; Quax WJ
FEBS J; 2019 Feb; 286(3):555-571. PubMed ID: 30589515
[TBL] [Abstract][Full Text] [Related]
35. Lipocalin 2 inversely regulates TRAIL sensitivity through p38 MAPK-mediated DR5 regulation in colorectal cancer.
Kim SL; Min IS; Park YR; Lee ST; Kim SW
Int J Oncol; 2018 Dec; 53(6):2789-2799. PubMed ID: 30221676
[TBL] [Abstract][Full Text] [Related]
36. Targeting the RNA-Binding Protein HuR in Cancer.
Finan JM; Sutton TL; Dixon DA; Brody JR
Cancer Res; 2023 Nov; 83(21):3507-3516. PubMed ID: 37683260
[TBL] [Abstract][Full Text] [Related]
37. Importin β1 protein-mediated nuclear localization of death receptor 5 (DR5) limits DR5/tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-induced cell death of human tumor cells.
Kojima Y; Nakayama M; Nishina T; Nakano H; Koyanagi M; Takeda K; Okumura K; Yagita H
J Biol Chem; 2011 Dec; 286(50):43383-93. PubMed ID: 22020938
[TBL] [Abstract][Full Text] [Related]
38. Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in established and primary glioma cell lines.
Jaganathan J; Petit JH; Lazio BE; Singh SK; Chin LS
Neurosurg Focus; 2002 Sep; 13(3):ecp1. PubMed ID: 15844877
[TBL] [Abstract][Full Text] [Related]
39. Quercetin enhances apoptotic effect of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in ovarian cancer cells through reactive oxygen species (ROS) mediated CCAAT enhancer-binding protein homologous protein (CHOP)-death receptor 5 pathway.
Yi L; Zongyuan Y; Cheng G; Lingyun Z; Guilian Y; Wei G
Cancer Sci; 2014 May; 105(5):520-7. PubMed ID: 24612139
[TBL] [Abstract][Full Text] [Related]
40. Anti-gout agent allopurinol exerts cytotoxicity to human hormone-refractory prostate cancer cells in combination with tumor necrosis factor-related apoptosis-inducing ligand.
Yasuda T; Yoshida T; Goda AE; Horinaka M; Yano K; Shiraishi T; Wakada M; Mizutani Y; Miki T; Sakai T
Mol Cancer Res; 2008 Dec; 6(12):1852-60. PubMed ID: 19074830
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
